A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

Vaccine

Volumn 24, Issue 49-50, 2006, Pages 7167-7174

  Dupont, Juan ^a   Altclas, Javier ^b   Lepetic, Alejandro ^c   Lombardo, Mónica ^d   Vázquez, Vicente ^a   Salgueira, Claudia ^b   Seigelchifer, Mauricio ^e   Arndtz, Nathaly ^g   Antunez, Ernesto ^d   von Eschen, Kenneth ^f   Janowicz, Zbigniew ^g  

^a HOSPITAL ESPAÑOL   (Argentina)

^b Department of Surgery   (Argentina)

^c Fundacion Centro de Estudios Infectologicos   (Argentina)

^d Solver Group   (Argentina)

^e PC Gen SA   (Argentina)

^f GLAXOSMITHKLINE   (United States)

^g Rhein Biotech GmbH   (Germany)

Author keywords

Adjuvant; Hepatitis B; Vaccines

Indexed keywords

AGB VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; RC 529; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; STANDARD; TREATMENT DURATION; VOMITING;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; EXCIPIENTS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; SUSPENSIONS;

EID: 33845366891     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.053     Document Type: Article

References (35)

1. Kane M. Global program for control of hepatitis B infection. Vaccine 13 (1995) S47-S49
2. Kao J.H., and Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2 (2002) 395-403
3. Yang H.I., Lu S.N., Liaw Y.F., You S.L., Sun C.A., Wang L.Y., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 (2002) 168-174
4. Yuen M.F., and Lai C.L. Treatment of chronic hepatitis B. Lancet Infect Dis 1 (2001) 232-241
5. Krugman S. Hepatitis B infection: strategies for clinicians. A roundtable discussion. Infections in medicine. Infect Dis Med Family Practices 8 (1991) S24-S31
6. The World Health Report. Fighting disease, Fostering development. Geneva, Switzerland: WHO; 1996, p. 33, 59.
7. Stevens C.E., Beasley R.P., Tsui J., and Lee W.-C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 292 (1975) 771-774
8. Stevens C.E., Toy P.T., Tong M.J., et al. Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. JAMA 253 (1985) 1740-1745
9. World Health Organization. Hepatitis B vaccine-making global progress. EPI Update 31, 1996. Geneva: World Health Organization.
10. World Health Organization. Hepatitis B. Available from: URL: www.who.int.
11. Ulrich J.T., and Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: Powell M.F., and Newman M.J. (Eds). Vaccine design: the subunit and adjuvant approach (1995), Plenum Press, New York 495-524
12. Thoelen S., De Clercq N., and Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 19 (2001) 2400-2403
13. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16 (1998) 708-714
14. Ambrosch F., Wiedermann G., Kundi M., et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 18 (2000) 2095-2101
15. Jacques P., Moens G., Desombere I., et al. The Immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 20 (2002) 3644-3649
16. Elliot GT. Non-GLP rabbit toxicology/immunogenicity study of a hepatitis B surface antigen/alum vaccine adjuvantized with the aminoalkyl glucosaminide 4-phoisphate (AGP) adjuvant, RC-529. Data on file at Corixa Corporation, Hamilton, Montana.
17. ®, Product Monograph, Laboratorio Pablo Cassará, January 10, 1998.
18. Lepetic A., Biscayart C., Seigelchifer M., Arduino R., and Stambulian D. Persistence of immunity and seroprotection 4 years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine. Vaccine 21 27-30 (2003) 4481-4485
19. Adkins J.C., and Wagstaff A.J. Recombinant hepatitis B vaccine. A review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs 10 2 (1998) 137-158
20. Galarza Cotera J. Evaluación de la Inmunogenicidad de una Vacuna DNA recombinante contra la hepatitis viral B. Med Mod 6 (1995) 14-16
21. Halder S.C., and Margolis H.S. Epidemiology of hepatitis B virus infections. In: Ellis R.W. (Ed). Hepatitis B vaccines in clinical practice (1993), Marcel Dekker, New York 141-157
22. Hyams K.C. Risk of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 20 (1995) 992-1000
23. Beasley R.P., and Hwang L.Y. Epidemiology of hepatocellular carcinoma. In: Vyas G.N., Dienstag J.L., and Hoofnagle J.H. (Eds). Viral hepatitis and liver disease (1984), Grune & Stratton, New York 209-224
24. Grob P., Hallauer J., Kane M., McCloy E., Meheus A., Roure C., et al. Hepatitis B. A serious public health threat. Viral hepatitis prevention board. Vaccine 16 (1998) S1-S2
25. Bonanni P. Universal hepatitis B immunization: infant, and infant plus adolescent immunization. Vaccine 16 (1998) S17-S22
26. Van Damme P., and Vorsters A. Hepatitis B control in Europe by universal vaccination programs: the situation in 2001. J Med Virol 67 (2002) 433-439
27. Halsey N.A. Discussion of Immunization Practices Advisory Committee/American Academy of Pediatrics Recommendations for universal infant hepatitis B vaccination. Ped Inf Dis J 12 (1993) 446-449
28. Guía para la Inmunización del Adulto. Editorial médica panamericana. 1990. Buenos Aires. Grupo de trabajo para la inmunización del adulto del ACP y de la Sociedad de Enfermedades Infecciosas de América. Publicado por el American College of Physicians, Philadelphia, Pennsylvania. Capítulo 7: Aspectos clínicos referentes a vacunas específicas. Hepatitis B. Página 67-77.
29. Mahoney F.J., and Kane M. Hepatitis B vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), W.B. Saunders Company, Philadelphia, USA 158-182
30. Thompson R.F. Travel & routine immunizations. A practical guide for the medical office (2003), Shoreland Inc., Milwaukee, USA p. 44
31. Leivie K., Beran J., Collard F., and Nguyen C. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years. Vaccine 20 (2002) 2579-2584
32. Center for Disease Control and Prevention. Update on Adult Immunization. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40(No. RR-12): 62.
33. Jilg W. Novel hepatitis B vaccines. Vaccine 16 (1998) S65-S68
34. Ambrosch F., Wiedermann G., Kundi M., et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 18 (2000) 2095-2101
35. Myers K.R., and Gustafson G.L. Adjuvants for human vaccine usage: a rational design. In: Stanley J., and Cryz Jr. (Eds). Vaccines and immunotherapy (1991), Pergamon Press, New York 404-411